This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
AB Science S.A.
Drug Names(s): AB8779
AB8779 is a novel, small molecule spleen tyrosine kinase (SYK) kinase inhibitor. SYK is a tyrosine kinase that is a mediator of signaling in a variety of inflammatory cells, including mast cells, macrophage, dendritic cells (DC), natural killer (NK) cells, neutrophils, and B-cells.
Preclinical data demonstrate that AB8779 has biological activity in vitro and in vivoin inflammatory murine models of asthma and rheumatoid arthritis. Additionally, it was shown that AB8779induces apoptosis of B-cell chronic lymphocytic leukemia cells and has anti-tumoral activity in vivo in amouse model of mantle cell lymphoma (MCL). It was further demonstrated that AB8779 has nocardiotoxicity in vitro on both human and rat cardiomyocytes. In vitro safety pharmacology andpharmacokinectics studies have also demonstrated that AB8779 has goodbioavailability and an absence of mutagenic activity.
Pink Sheet FDA RECALLS & COURT ACTIONS: Feb. 3, 1993
Additional information available to subscribers only: